Goldman Sachs Expected to Outperform Peers and 3 Stock Analyses Buzzing Now
Forest Laboratories Inc. (NYSE:FRX): Current price $37.07
Susquehanna believes Forest Laboratories Inc.’s investors are hoping for a major restructuring or takeout, however, the firm does not view either scenario as likely. Susquehanna lowered their estimates and cited management guidance, lower revenues, and significant spending on new product launches. The firm maintains their Negative rating and $29 price target.
Teradyne Inc. (NYSE:TER): Current price $16.6599
After conducting channel checks, Stifel Nicolaus believes that the SoC test space may be starting to improve and poised to rebound in the first half of 2013. The firm thinks that Teradyne likely saw a pickup in new SoC test orders in December and they maintain a Buy rating on the stock.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
Onyx Pharmaceuticals Inc. (NASDAQ:ONXX): Current price $80.75
Baird lowered their price target on Onyx Pharmaceuticals Inc., to reflect the dilutive nature of their secondary offering. The firm has no change to their positive stance and remains buyers of the shares, citing bullish signals from their recent Kyprolis survey which is expected to ramp in 2013. Shares are Outperform rated.
The Goldman Sachs Group, Inc. (NYSE:GS): Current price $139.10
Following the company’s better than expected fourth quarter results, Wells Fargo said that they expect Goldman Sachs Group, Inc.’s shares to outperform peers. However, Wells believes that concern over the sustainability of the results will dampen longer-term enthusiasm. The firm has a Market Perform rating on Goldman shares.
Investing Insights: Goldman Sachs Earnings: First Year of Revenue Growth Since 2009.